There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Maxwell Elliott |
| Institution: | Duke University |
| Department: | Psychology and Neuroscience |
| Country: | |
| Proposed Analysis: | Our goal is to quantify and validate the pace of biological aging in the ADNI sample. Specifically, we propose quantifying the pace of biological aging using a recently developed DNA methylation algorithm. This algorithm was designed to measure the pace of biological aging based on declines in the cardiovascular, metabolic, renal, hepatic, immune, periodontal, and pulmonary systems. This algorithm was developed in the Dunedin Study, and is based on tracking 19 biomarkers at ages 26, 32, 38, and 45 years in each participant. This methylation algorithm is called the Dunedin Study Pace of Aging methylation score (DunedinPoAm). First, we will apply the DunedinPoAm to the methylation data in ADNI to calculate the pace of biological aging in each participant. Second, we will validate and extend the DunedinPoAm in the ADNI dataset by testing whether the DunedinPoAm is accelerated in participants with ADRD and MCI. Third, we will test whether ADNI participants with an accelerated DunedinPoAm have accelerated trajectories of cognitive decline. Fourth, we will test whether ADNI participants with an accelerated DunedinPoAm have signs of neurodegeneration as measured by the CSF biomarker neurofilament light. Fifth, we will test whether ADNI participants with a faster DunedinPoAm have signs of accelerated brain aging using the longitudinal MRI data in ADNI. All together this project will help to develop and validate a methylation-based measure of the pace of biological aging. By extending this measure past the Dunedin Study to older adults in ADNI, we will be able to test the generalizability of DunedinPoAm and its utility in early screening for ADRD risk. |
| Additional Investigators | |
| Investigator's Name: | Ahmad Hariri |
| Proposed Analysis: | Our goal is to quantify and validate the pace of biological aging in the ADNI sample. Specifically, we propose quantifying the pace of biological aging using a recently developed DNA methylation algorithm. This algorithm was designed to measure the pace of biological aging based on declines in the cardiovascular, metabolic, renal, hepatic, immune, periodontal, and pulmonary systems. This algorithm was developed in the Dunedin Study, and is based on tracking 19 biomarkers at ages 26, 32, 38, and 45 years in each participant. This methylation algorithm is called the Dunedin Study Pace of Aging methylation score (DunedinPoAm). First, we will apply the DunedinPoAm to the methylation data in ADNI to calculate the pace of biological aging in each participant. Second, we will validate and extend the DunedinPoAm in the ADNI dataset by testing whether the DunedinPoAm is accelerated in participants with ADRD and MCI. Third, we will test whether ADNI participants with an accelerated DunedinPoAm have accelerated trajectories of cognitive decline. Fourth, we will test whether ADNI participants with an accelerated DunedinPoAm have signs of neurodegeneration as measured by the CSF biomarker neurofilament light. Fifth, we will test whether ADNI participants with a faster DunedinPoAm have signs of accelerated brain aging using the longitudinal MRI data in ADNI. All together this project will help to develop and validate a methylation-based measure of the pace of biological aging. By extending this measure past the Dunedin Study to older adults in ADNI, we will be able to test the generalizability of DunedinPoAm and its utility in early screening for ADRD risk. |
| Investigator's Name: | Terrie Moffitt |
| Proposed Analysis: | Our goal is to quantify and validate the pace of biological aging in the ADNI sample. Specifically, we propose quantifying the pace of biological aging using a recently developed DNA methylation algorithm. This algorithm was designed to measure the pace of biological aging based on declines in the cardiovascular, metabolic, renal, hepatic, immune, periodontal, and pulmonary systems. This algorithm was developed in the Dunedin Study, and is based on tracking 19 biomarkers at ages 26, 32, 38, and 45 years in each participant. This methylation algorithm is called the Dunedin Study Pace of Aging methylation score (DunedinPoAm). First, we will apply the DunedinPoAm to the methylation data in ADNI to calculate the pace of biological aging in each participant. Second, we will validate and extend the DunedinPoAm in the ADNI dataset by testing whether the DunedinPoAm is accelerated in participants with ADRD and MCI. Third, we will test whether ADNI participants with an accelerated DunedinPoAm have accelerated trajectories of cognitive decline. Fourth, we will test whether ADNI participants with an accelerated DunedinPoAm have signs of neurodegeneration as measured by the CSF biomarker neurofilament light. Fifth, we will test whether ADNI participants with a faster DunedinPoAm have signs of accelerated brain aging using the longitudinal MRI data in ADNI. All together this project will help to develop and validate a methylation-based measure of the pace of biological aging. By extending this measure past the Dunedin Study to older adults in ADNI, we will be able to test the generalizability of DunedinPoAm and its utility in early screening for ADRD risk. |
| Investigator's Name: | Avshalom Caspi |
| Proposed Analysis: | Our goal is to quantify and validate the pace of biological aging in the ADNI sample. Specifically, we propose quantifying the pace of biological aging using a recently developed DNA methylation algorithm. This algorithm was designed to measure the pace of biological aging based on declines in the cardiovascular, metabolic, renal, hepatic, immune, periodontal, and pulmonary systems. This algorithm was developed in the Dunedin Study, and is based on tracking 19 biomarkers at ages 26, 32, 38, and 45 years in each participant. This methylation algorithm is called the Dunedin Study Pace of Aging methylation score (DunedinPoAm). First, we will apply the DunedinPoAm to the methylation data in ADNI to calculate the pace of biological aging in each participant. Second, we will validate and extend the DunedinPoAm in the ADNI dataset by testing whether the DunedinPoAm is accelerated in participants with ADRD and MCI. Third, we will test whether ADNI participants with an accelerated DunedinPoAm have accelerated trajectories of cognitive decline. Fourth, we will test whether ADNI participants with an accelerated DunedinPoAm have signs of neurodegeneration as measured by the CSF biomarker neurofilament light. Fifth, we will test whether ADNI participants with a faster DunedinPoAm have signs of accelerated brain aging using the longitudinal MRI data in ADNI. All together this project will help to develop and validate a methylation-based measure of the pace of biological aging. By extending this measure past the Dunedin Study to older adults in ADNI, we will be able to test the generalizability of DunedinPoAm and its utility in early screening for ADRD risk. |
| Investigator's Name: | Annchen Knodt |
| Proposed Analysis: | Our goal is to quantify and validate the pace of biological aging in the ADNI sample. Specifically, we propose quantifying the pace of biological aging using a recently developed DNA methylation algorithm. This algorithm was designed to measure the pace of biological aging based on declines in the cardiovascular, metabolic, renal, hepatic, immune, periodontal, and pulmonary systems. This algorithm was developed in the Dunedin Study, and is based on tracking 19 biomarkers at ages 26, 32, 38, and 45 years in each participant. This methylation algorithm is called the Dunedin Study Pace of Aging methylation score (DunedinPoAm). First, we will apply the DunedinPoAm to the methylation data in ADNI to calculate the pace of biological aging in each participant. Second, we will validate and extend the DunedinPoAm in the ADNI dataset by testing whether the DunedinPoAm is accelerated in participants with ADRD and MCI. Third, we will test whether ADNI participants with an accelerated DunedinPoAm have accelerated trajectories of cognitive decline. Fourth, we will test whether ADNI participants with an accelerated DunedinPoAm have signs of neurodegeneration as measured by the CSF biomarker neurofilament light. Fifth, we will test whether ADNI participants with a faster DunedinPoAm have signs of accelerated brain aging using the longitudinal MRI data in ADNI. All together this project will help to develop and validate a methylation-based measure of the pace of biological aging. By extending this measure past the Dunedin Study to older adults in ADNI, we will be able to test the generalizability of DunedinPoAm and its utility in early screening for ADRD risk. |
| Investigator's Name: | Renate Houts |
| Proposed Analysis: | Our goal is to quantify and validate the pace of biological aging in the ADNI sample. Specifically, we propose quantifying the pace of biological aging using a recently developed DNA methylation algorithm. This algorithm was designed to measure the pace of biological aging based on declines in the cardiovascular, metabolic, renal, hepatic, immune, periodontal, and pulmonary systems. This algorithm was developed in the Dunedin Study, and is based on tracking 19 biomarkers at ages 26, 32, 38, and 45 years in each participant. This methylation algorithm is called the Dunedin Study Pace of Aging methylation score (DunedinPoAm). First, we will apply the DunedinPoAm to the methylation data in ADNI to calculate the pace of biological aging in each participant. Second, we will validate and extend the DunedinPoAm in the ADNI dataset by testing whether the DunedinPoAm is accelerated in participants with ADRD and MCI. Third, we will test whether ADNI participants with an accelerated DunedinPoAm have accelerated trajectories of cognitive decline. Fourth, we will test whether ADNI participants with an accelerated DunedinPoAm have signs of neurodegeneration as measured by the CSF biomarker neurofilament light. Fifth, we will test whether ADNI participants with a faster DunedinPoAm have signs of accelerated brain aging using the longitudinal MRI data in ADNI. All together this project will help to develop and validate a methylation-based measure of the pace of biological aging. By extending this measure past the Dunedin Study to older adults in ADNI, we will be able to test the generalizability of DunedinPoAm and its utility in early screening for ADRD risk. |
| Investigator's Name: | Ethan Whitman |
| Proposed Analysis: | Our goal is to quantify and validate the pace of biological aging in the ADNI sample. Specifically, we propose quantifying the pace of biological aging using a recently developed DNA methylation algorithm. This algorithm was designed to measure the pace of biological aging based on declines in the cardiovascular, metabolic, renal, hepatic, immune, periodontal, and pulmonary systems. This algorithm was developed in the Dunedin Study, and is based on tracking 19 biomarkers at ages 26, 32, 38, and 45 years in each participant. This methylation algorithm is called the Dunedin Study Pace of Aging methylation score (DunedinPoAm). First, we will apply the DunedinPoAm to the methylation data in ADNI to calculate the pace of biological aging in each participant. Second, we will validate and extend the DunedinPoAm in the ADNI dataset by testing whether the DunedinPoAm is accelerated in participants with ADRD and MCI. Third, we will test whether ADNI participants with an accelerated DunedinPoAm have accelerated trajectories of cognitive decline. Fourth, we will test whether ADNI participants with an accelerated DunedinPoAm have signs of neurodegeneration as measured by the CSF biomarker neurofilament light. Fifth, we will test whether ADNI participants with a faster DunedinPoAm have signs of accelerated brain aging using the longitudinal MRI data in ADNI. All together this project will help to develop and validate a methylation-based measure of the pace of biological aging. By extending this measure past the Dunedin Study to older adults in ADNI, we will be able to test the generalizability of DunedinPoAm and its utility in early screening for ADRD risk. |
| Investigator's Name: | Karen Sugden |
| Proposed Analysis: | Our goal is to quantify and validate the pace of biological aging in the ADNI sample. Specifically, we propose quantifying the pace of biological aging using a recently developed DNA methylation algorithm. This algorithm was designed to measure the pace of biological aging based on declines in the cardiovascular, metabolic, renal, hepatic, immune, periodontal, and pulmonary systems. This algorithm was developed in the Dunedin Study, and is based on tracking 19 biomarkers at ages 26, 32, 38, and 45 years in each participant. This methylation algorithm is called the Dunedin Study Pace of Aging methylation score (DunedinPoAm). First, we will apply the DunedinPoAm to the methylation data in ADNI to calculate the pace of biological aging in each participant. Second, we will validate and extend the DunedinPoAm in the ADNI dataset by testing whether the DunedinPoAm is accelerated in participants with ADRD and MCI. Third, we will test whether ADNI participants with an accelerated DunedinPoAm have accelerated trajectories of cognitive decline. Fourth, we will test whether ADNI participants with an accelerated DunedinPoAm have signs of neurodegeneration as measured by the CSF biomarker neurofilament light. Fifth, we will test whether ADNI participants with a faster DunedinPoAm have signs of accelerated brain aging using the longitudinal MRI data in ADNI. All together this project will help to develop and validate a methylation-based measure of the pace of biological aging. By extending this measure past the Dunedin Study to older adults in ADNI, we will be able to test the generalizability of DunedinPoAm and its utility in early screening for ADRD risk. UPDATED (2021-06-15) :Epigenetic clocks are increasingly used to estimate biological aging; however, their relationship with age-related cognitive impairment is not well understood. We used data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to test the association between blood-based DNA methylation measures of biological aging and cognitive impairment. Measures of aging include: the first generation of methylation algorithms that were trained on date-of-birth; the second generation of algorithms that were trained on cross-sectional assessments of health to predict mortality; and the third generation that were trained on longitudinally-observed age-related changes in health. We tested these three ‘generations’ of algorithms against the following measures of cognitive impairment: clinical diagnosis of dementia and mild cognitive impairment; scores on AD/ADRD screening tests (Alzheimer’s Disease Assessment Scale; Mini-Mental State Examination; Montreal Cognitive Assessment); and scores on cognitive tests (Rey Auditory Verbal Learning Test; Logical Memory Test; Trail Making Test). The first generation (Horvath and Hannum DNA methylation age clocks) and the second generation (PhenoAge and GrimAge) measures of epigenetic aging were not consistently associated with measures of cognitive impairment in older adults. In contrast, a third generation blood-based DNA methylation measure of biological aging that was trained on longitudinally measured biological decline, the Dunedin Pace of Aging methylation measure (DunedinPoAm4x), was associated with clinical diagnosis of Alzheimer’s Disease and with poorer scores on AD/ADRD screening tests and cognitive tests. Third-generation epigenetic age acceleration clocks could prove valuable tools for quantifying risks and evaluating interventions in cognitive aging. |
